Pfizer's Paxlovid receives full FDA approval for Covid treatment.

The FDA has granted full approval to Pfizer's COVID-19 oral antiviral pill, Paxlovid, for use in adults at high risk of severe disease. The drug is given as a five-day treatment course and should be initiated as soon as possible after a COVID-19 diagnosis. Paxlovid has been shown to be most effective among patients who have not received a COVID-19 vaccine and those who have not been previously infected. The federal government owns 9.6 million doses of Paxlovid, with about 4 million doses currently available at provider sites nationwide.